RECRUITING

AURORA Study-A Transformative Approach to Support PrEP Medication Persistence

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is designed to test the hypothesis that, compared to oral PrEP, use of CAB-LA in underserved populations in a real-world setting supported by a digital health companion program will be associated with greater medication adherence, persistence, retention-in-care, and improved PROs. Patients in the study will receive current standard care for HIV prevention and be offered enrollment in the digital health companion program. Goal of the study is to evaluate medication adherence and persistence in patients receiving CAB-LA vs oral PrEP and who engage with a digital health companion program.

Official Title

AURORA Study-A Transformative Approach Utilizing Behavioral Economics, Education, and Data Science to Support Patients Initiating PrEP With Retention-in-care and Medication Persistence

Quick Facts

Study Start:2023-11-30
Study Completion:2025-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06072443

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Initiation of or current user of PrEP with CAB-LA, daily FTC/TDF, or daily FTC/TAF prescribed in accordance with the WVHR standard of care practices (based practices on CDC PrEP 2021 Clinical Practice Guidelines) by a licensed HCP
  2. * PrEP dispensed by WVHR pharmacy
  3. * Access to a smart phone
  1. * Receiving HIV PrEP care outside of WVHR
  2. * Positive HIV diagnosis
  3. * Contraindication to oral or injectable PrEP therapy
  4. * Receiving oral bridging therapy prior to injectable PrEP therapy

Contacts and Locations

Study Contact

Angie Settle, DNP, APRN
CONTACT
304-414-5930
ASettle@wvhealthright.org
Rhonda Francis, CPhT, Adv
CONTACT
304-414-5930
Rfrancis@wvhealthright.org

Study Locations (Sites)

West Virginia Health Right
Charleston, West Virginia, 25311
United States

Collaborators and Investigators

Sponsor: WV Health Right, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-30
Study Completion Date2025-06-30

Study Record Updates

Study Start Date2023-11-30
Study Completion Date2025-06-30

Terms related to this study

Keywords Provided by Researchers

  • PrEP
  • HIV Prevention

Additional Relevant MeSH Terms

  • HIV Infections